Alexander Sacher

Dr. Alexander Sacher


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MJMayank Sujeetkumar Jha
Mayank Sujeetkumar Jha
DSDavid Song
David Song
AKAndrew Kung
Andrew Kung
SLSamantha Lo
Samantha Lo
ASAlexander Sacher
Alexander Sacher
SGSeth Goldbarg
Seth Goldbarg
Background: Patients with arrhythmias, particularly paroxysmal supraventricular tachycardia (PSVT), face an increased risk of cardiac complications. Currently, non-parenteral medications for rapid PSVT cessation are lacking. Etripamil, a novel intranasal, short-acting calcium channel blocker, offers a rapid onset and the potential for unsupervised PSVT management. However, data on its use in arrhythmia management remain limited. Aims: We aimed to assess the efficacy and safety of 70 mg of etripamil compared with placebo in the treatment of PSVT. Methods: We systematically searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) from inception to April 2025. We calculated pooled risk ratios (RRs) with 95% confidence intervals (CIs) using random or common effects models, depending on the heterogeneity. Results: Four RCTs including 540 patients were analyzed. Etripamil demonstrated higher conversion rates to the sinus rhythm at 15 min (RR 1.84 [95% CI: 1.32–2.48]), 30 min (RR 1.80 [95% CI: 1.38–2.35]), and 60 min (RR 1.24 [95% CI: 1.04–1.48]). PSVT recurrence rates were similar between groups (RR 0.52 [95% CI: 0.20–1.34]). Adverse events (AEs) and severe AEs were comparable between etripamil and the placebo. Etripamil was associated with higher rates of nasal discomfort, nasal congestion, rhinorrhea, and epistaxis but not with increased bradyarrhythmia, atrial fibrillation, or non-sustained ventricular tachycardia. Conclusions: Etripamil appears to be a promising treatment for cardiac arrhythmias. Larger long-term RCTs are needed to confirm its safety and efficacy in clinical practice.

9 October 2025 in JACC: Case Reports
Verified
Journal Article
Open access
ASAlexander Sacher
Alexander Sacher
RARafsan Ahmed
Rafsan Ahmed
AKAndrew Kung
Andrew Kung
KPKrishnadev Pillai
Krishnadev Pillai
JKJasneel Kahlam
Jasneel Kahlam
Giant cell myocarditis (GCM) is a rare, rapidly progressive inflammatory cardiomyopathy, often manifesting with ventricular arrhythmias or heart failure. Early recognition and immunosuppressive therapy are crucial for improving outcomes. A 65-year-old man undergoing preoperative evaluation for hip surgery was found to have a wide complex tachycardia. He reported palpitations and dizziness but denied chest pain. Troponin was significantly elevated (5,206 ng/L, peaking at 5,647 ng/L). Transthoracic echocardiography showed reduced left ventricular ejection fraction (35%-40%), and cardiac magnetic resonance suggested myocarditis. Endomyocardial biopsy confirmed GCM. The patient was started on pulse-dose steroids, tacrolimus, and mycophenolate mofetil, resulting in swift improvement as indicated by rapidly downtrending troponin levels. He was ultimately listed for heart transplantation. GCM often manifests with ventricular arrhythmias and rapid clinical deterioration. This case underscores the importance of recognizing myocarditis as a cause of ventricular tachycardia, particularly in patients with elevated troponins and nonobstructive coronary artery disease. Early diagnosis and immunosuppression are key to improving prognosis. Consider myocarditis in patients with ventricular tachycardia and high troponins and nonobstructive coronary artery disease. Early recognition and immunosuppressive therapy are critical for management of GCM. Cardiac magnetic resonance and biopsy are essential for diagnosis. Orthotopic heart transplantation should be considered in all cases of GCM owing to the associated high mortality rates.

17 March 2025 in JACC: Case Reports
Verified
Journal Article
Open access
ASAlexander Sacher
Alexander Sacher
RARafsan Ahmed
Rafsan Ahmed
AKAndrew Kung
Andrew Kung
JKJasneel Kahlam
Jasneel Kahlam
Antiphospholipid syndrome (APS) is known for thrombotic events and pregnancy complications, but its association with myocarditis is rare and poorly understood. A 44-year-old woman presented with acute chest tightness, elevated cardiac biomarkers, and severe anemia. Diagnostic workup revealed ST-segment changes on electrocardiogram, preserved left ventricular function on echocardiography, and myocardial inflammation on cardiac magnetic resonance imaging, suggestive of acute myocarditis. Positive antiphospholipid antibodies confirmed APS. She was managed with close multidisciplinary follow-up. APS-associated myocarditis poses diagnostic challenges because of its atypical presentation and overlap with other cardiac conditions. This case highlights the role of cardiac magnetic resonance imaging in diagnosing myocarditis early, guiding management strategies, and the need for heightened clinical suspicion in APS patients presenting with cardiac symptoms.